MedTrace Logo

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

NCT07175285 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 223

Last updated 2026-05-18

No results posted yet for this study

Summary

The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

DRUG

Current standard of care treatment options

According to the product label

Sponsors & Collaborators

Principal Investigators

  • Bristol Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-08
Primary Completion
2028-03-24
Completion
2032-10-05
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • Canada
  • France
  • Germany
  • Israel
  • Italy
  • Japan
  • Puerto Rico
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07175285 on ClinicalTrials.gov